Skip to main content
. 2018 Dec 18;8:17938. doi: 10.1038/s41598-018-36041-8

Figure 5.

Figure 5

Mapping of the edges for top-ranked degree centralities onto HIV 3D protease structures for the significantly larger (left) and smaller (right) distances observed in resistant ensembles for 8 FDA-approved protease inhibitor complexes, namely ATV (a), DRV (b), FPV (c), IDV (d), LPV (e), NFV (f), SQV (g) and TPV (h).